Finasteride Tablet, Film Coated
NDC Package 17856-0090-1

11-digit billing NDC: 17856009001

Package Information

Finasteride tablets is finasteride is contraindicated in the following:Hypersensitivity to any component of this medication.Pregnancy. This formulation utilizes a tablet, film coated delivery system. Marketed by Atlantic Biologicals Corps, this product is identified by NDC 17856-0090 and is authorized under FDA application ANDA090121.

Identification & Billing

NDC Package Code
17856-0090-1
Package Description
1 TABLET, FILM COATED in 1 POUCH
Product Code
11-Digit Billing Format
17856009001
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Finasteride
Non-Proprietary Name
Finasteride
Substance Name
Finasteride
Dosage Form
Tablet, Film Coated - A solid dosage form that contains medicinal substances with or without suitable diluents and is coated with a thin layer of a water-insoluble or water-soluble polymer.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Usage Information
Finasteride is contraindicated in the following:Hypersensitivity to any component of this medication.Pregnancy. Finasteride use is contraindicated in women when they are or may potentially be pregnant. Because of the ability of Type II 5α-reductase inhibitors to inhibit the conversion of testosterone to 5α-dihydrotestosterone (DHT), finasteride may cause abnormalities of the external genitalia of a male fetus of a pregnant woman who receives finasteride. If this drug is used during pregnancy, or if pregnancy occurs while taking this drug, the pregnant woman should be apprised of the potential hazard to the male fetus. In female rats, low doses of finasteride administered during pregnancy have produced abnormalities of the external genitalia in male offspring. [See also , , and .] Warnings and Precautions (5.3)Use in Specific Populations (8.1)How Supplied/Storage and Handling (16)Patient Counseling Information (17.2)

Regulatory & Marketing

Labeler Name
Atlantic Biologicals Corps
Product Type
Human Prescription Drug
FDA Application #
ANDA090121
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
05-28-2010
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 17856-0090-1 identifies a specific commercial package of 1 tablet, film coated in 1 pouch of Finasteride, a human prescription drug labeled by Atlantic Biologicals Corps. This tablet, film coated is formulated for oral use and contains finasteride as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Atlantic Biologicals Corps on May 28, 2010. The current certification is valid through December 31, 2026.

How is this Atlantic Biologicals Corps product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 17856009001. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
17856-0090-1
11-Digit CMS (5-4-2)
17856-0090-01

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.